Infusion includes Rs 10,300 crore as equity capital into RINL, conversion of Rs 1,140 crore working capital loan as 7% non-cumulative preference share capital redeemable after 10 years
As per the report, record exports and a resilient domestic demand made sugar one of the few sectors to witness strong revenue growth in the Covid-19 affected in 1HFY21.